<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234516</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #7855</org_study_id>
    <nct_id>NCT04234516</nct_id>
  </id_info>
  <brief_title>Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder</brief_title>
  <official_title>Functional Brain Mechanisms Underlying the Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to examine the effect of buprenorphine on suicidal ideation in individuals&#xD;
      with opioid use disorder, and to investigate the functional brain activity related to its&#xD;
      potential anti-suicidal effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current opioid epidemic is an urgent public health problem, contributing significantly to&#xD;
      the climbing U.S. suicide rates over the past two decades.&#xD;
&#xD;
      Although initially rewarding, chronic opioid use leads to tolerance and escalating negative&#xD;
      affective states. This may promote suicidal ideation and may further impair decision-making&#xD;
      functions leading to suicidal behavior.&#xD;
&#xD;
      Buprenorphine, a treatment for opioid use disorder (OUD), has promise in reducing suicidal&#xD;
      ideation. However, the neural mechanism of its anti-suicidal properties remains unknown.&#xD;
      Blocking kappa opioid receptors is one mechanism of buprenorphine hypothesized to reverse the&#xD;
      negative emotional sensitivity in OUD and thus may underlie its anti-suicidal effects.&#xD;
&#xD;
      In this morphine-controlled study, we will examine the effect of buprenorphine on the&#xD;
      functional activity of brain regions involved in negative emotional reactivity and&#xD;
      investigate whether this effect is associated with its anti-suicidal properties.&#xD;
&#xD;
      Buprenorphine has a different mechanism of action than currently available antidepressants&#xD;
      and anti-suicidal medications. Understanding this mechanism can help refine its use in this&#xD;
      context. Success will guide a future larger study to elucidate molecular mechanisms&#xD;
      underlying anti-suicidal properties of buprenorphine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI leaving the institute&#xD;
  </why_stopped>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Actual">June 10, 2021</completion_date>
  <primary_completion_date type="Actual">June 10, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Double blind, double dummy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Beck Scale for Suicidal Ideation (SSI) scores from baseline to Week 2 post-treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>Clinician-based questionnaire measuring level of suicidal ideas over the last 7 days; 21 items scored 0 to 2; total score ranges from 0 to 38 (last 2 items not counted), higher scores mean more intense suicidal ideas.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in functional magnetic resonance imaging (fMRI) blood oxygen-level dependent (BOLD) signal in the amygdala in response to negative vs. neutral pictures from baseline to Week 2 post-treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>fMRI negative picture task administered at baseline and week 2 post-treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Opioid-use Disorder</condition>
  <condition>Suicidal Ideation</condition>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sublingual buprenorphine-naloxone films</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral morphine sulphate tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film</intervention_name>
    <description>3 x 8 mg sublingual buprenorphine/naloxone films wrapped inside one Listerine strip at 8 pm daily + oral placebo pills q.i.d.</description>
    <arm_group_label>Buprenorphine</arm_group_label>
    <other_name>buprenorphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulfate 30 mg</intervention_name>
    <description>oral morphine sulphate 30 mg immediate release tablets q.i.d. + two sublingual Listerine strips at 8 pm</description>
    <arm_group_label>Morphine</arm_group_label>
    <other_name>morphine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-55 years old&#xD;
&#xD;
          -  Current opioid use disorder (mild, moderate or severe)&#xD;
&#xD;
          -  Seeking treatment for opioid use disorder and willing to accept agonist-based therapy&#xD;
             and be stabilized on buprenorphine when study is over&#xD;
&#xD;
          -  Active suicidal ideation&#xD;
&#xD;
          -  Participant must agree to voluntary admission to New York State Psychiatric Institute&#xD;
             (NYSPI) inpatient research unit with confirmed bed availability&#xD;
&#xD;
          -  Capacity to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of chronic pain of sufficient severity as to require ongoing pain management&#xD;
             with opioids&#xD;
&#xD;
          -  Current active psychosis or mania&#xD;
&#xD;
          -  Current moderate-severe alcohol, benzodiazepine, or other drug use likely to require a&#xD;
             medical detoxification&#xD;
&#xD;
          -  Unstable epilepsy or other neurological disorder&#xD;
&#xD;
          -  A history of prior head trauma with evidence of cognitive impairment. Participants who&#xD;
             endorse a history of prior head trauma will be administered Trail-making A and B test.&#xD;
             Those who score 1.5 standard deviations below the mean on Trail- making A or B will be&#xD;
             excluded from study participation&#xD;
&#xD;
          -  Active significant medical illness that, in the opinion of the study physician, would&#xD;
             make study participation hazardous to the participant or compromise study findings or&#xD;
             would prevent the participant from completing the study (e.g., uncompensated heart&#xD;
             failure, cirrhosis or end-stage liver disease)&#xD;
&#xD;
          -  Liver Function Tests (ALT, AST) greater than 5 times upper limit of normal&#xD;
&#xD;
          -  On methadone-maintenance therapy&#xD;
&#xD;
          -  Contraindication to any study treatment (e.g., Known allergy or sensitivity to&#xD;
             buprenorphine)&#xD;
&#xD;
          -  Pending legal action or other reasons that might prevent an individual from completing&#xD;
             the study&#xD;
&#xD;
          -  If female, currently pregnant or breastfeeding, or planning on conception&#xD;
&#xD;
          -  Inadequate understanding of English&#xD;
&#xD;
          -  Metal implants or paramagnetic objects contained within the body (including heart&#xD;
             pacemaker, shrapnel, or surgical prostheses) which may present a risk to the subject&#xD;
             or interfere with the MRI scan&#xD;
&#xD;
          -  Claustrophobia significant enough to interfere with MRI scanning&#xD;
&#xD;
          -  Weight over 350 lbs or inability to fit into MRI scanner&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mina M Rizk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Mina.Rizk</investigator_full_name>
    <investigator_title>Paul Janssen Postdoctoral Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Suicidal Ideation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

